ArticleBMC cancer2026
IL-8 positive cancer-associated fibroblasts drive breast cancer progression and immune evasion: insights from GWAS and single-cell transcriptomics.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-8 (IL-8) is a key inflammatory mediator in the tumor microenvironment (TME), where cancer-associated fibroblasts (CAFs) drive breast cancer progression by secreting various cytokines. This study investigates the role of IL-8 positive CAFs in breast cancer pathogenesis and explores their underlying molecular mechanisms.
methodsWe performed Mendelian randomization (MR) analysis to evaluate the potential causal relationship between IL-8 levels and breast cancer risk using genome-wide association study (GWAS) data. Subpopulations of IL-8 + CAFs were identified through single-cell RNA sequencing from the GSE180286 dataset. The scPagwas algorithm was used to integrate single-cell RNA sequencing data with GWAS data to investigate the relationship between IL-8 + CAFs and breast cancer. Using the BayesPrism package, we performed Bayesian deconvolution to classify patients into high and low IL-8 + CAFs groups for prognostic and therapeutic sensitivity analyses. Cell-cell interactions were examined using the CellChat package. Additionally, in vitro experiments were performed to confirm the pro-tumor effects of IL-8 + CAFs.
resultsThe MR analysis revealed a causal effect between IL-8 exposure and increased breast cancer risk (OR = 1.251). Compared to IL-8-CAFs, IL-8 + CAFs exhibited a significant association with breast cancer. Survival analysis revealed that patients with high abundance of IL-8 + CAFs experienced a poorer prognosis. Moreover, patients in the high IL-8 + CAFs group were sensitive to most chemotherapy drugs, but demonstrated significant resistance to immunotherapy and immune evasion. Notably, significant interactions were observed between IL-8 + CAFs and various cells within the TME. Patients with high abundance of IL-8 + CAFs presented with increased stromal, immune, and ESTIMATE scores, along with reduced tumor purity scores. In vitro experiments confirmed that IL-8 significantly promoted tumor cell proliferation, colony formation, migration, and invasion.
conclusionIL-8 + CAFs represent a pivotal cellular subpopulation driving breast cancer progression and immune evasion, highlighting their potential as targets for personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.